0

5

10

15

20

25

30

35

40

Blunt Penetrating

PlaceborFVIIa

Pat

ient

s (%

)

n=20

n=8

n=9

n=4

P=0.03

P=0.068

Adapted from Rizoli S. Canadian Anesthesiologists’ Society Annual Meeting 2007.

Need for Massive Transfusion (>20 units RBC): A Secondary Analysis

Comparison Odds ratio CI P value Entire patient cohort (unadjusted)

All rFVIIa vs. no rFVIIa 2.41 1.56-3.67 <0.0001 Late rFVIIa vs. no rFVIIa 4.88 2.64-8.98 <0.0001 Early rFVIIa vs. no rFVIIa 1.39 0.79-2.43 0.30 Entire patient cohort (adjusted) All rFVIIa vs. no rFVIIa 1.04 0.60-1.81 0.90 Late rFVIIa vs. no rFVIIa 1.12 0.51-2.49 0.90 Early rFVIIa vs. no rFVIIa 0.99 0.51-1.91 0.80

Only rFVIIa-treated patients (adjusted) Early rFVIIa vs. no rFVIIa 0.41 0.18-0.92 0.30

Adapted from Karkouti et al. Can an J Anaesth 2006;53(8):802-9.

Risk of Adverse Events in 114 rFVIIa-treated Patients

Placebo (n=63)

rFVIIa (n=49) Reduction P-value

RBC (unit) 6.35 2.95 3.40 <0.01

FFP (mL) 1,320 660 660 <0.01

Platelets (mL) 263 100 163 0.04

Adapted from Rizoli S. Canadian Anesthesiologists Society 2007.

Blood Transfusion Requirementin Coagulopathic Patients